Synt:em SA

Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain. By Mel

The French government has always been vocal about its desire to turn France into a leader in innovation and high tech industries. On the pharma side, it certainly influenced heavily the success of San

Neuro3d's €31.5 million third round late in 2004 was one of France's largest private biotech financings for years. But none of the investors are looking to France to provide the exit opportunities, wh

Sonus' proposed acquisition of Synt:em answers the French biotech's call for a financeable owner with upside, preferably in the US. For many European biotech firms, M&A may be their only way out of a